These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33277732)

  • 21. Synergism between metallic nanoparticles and antibiotics.
    Agreles MAA; Cavalcanti IDL; Cavalcanti IMF
    Appl Microbiol Biotechnol; 2022 Jun; 106(11):3973-3984. PubMed ID: 35670851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanotargeting of Resistant Infections with a Special Emphasis on the Biofilm Landscape.
    Alabresm A; Chandler SL; Benicewicz BC; Decho AW
    Bioconjug Chem; 2021 Aug; 32(8):1411-1430. PubMed ID: 34319073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nano-therapeutics: A revolution in infection control in post antibiotic era.
    Zaidi S; Misba L; Khan AU
    Nanomedicine; 2017 Oct; 13(7):2281-2301. PubMed ID: 28673854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging antibacterial nanomedicine for enhanced antibiotic therapy.
    Wang S; Gao Y; Jin Q; Ji J
    Biomater Sci; 2020 Dec; 8(24):6825-6839. PubMed ID: 32996490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combating Antibiotic-Resistant Gram-Negative Bacteria Strains with Tetracycline-Conjugated Carbon Nanoparticles.
    Kim TH; Raiz A; Unni AD; Murhekar S; Donose BC; Floetenmeyer M; Cock IE; Brown CL
    Adv Biosyst; 2020 Sep; 4(9):e2000074. PubMed ID: 32803868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of nanotechnology in combating multi-drug resistant bacteria.
    Singh R; Smitha MS; Singh SP
    J Nanosci Nanotechnol; 2014 Jul; 14(7):4745-56. PubMed ID: 24757944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors pivotal for designing of nanoantimicrobials: an exposition.
    Jamil B; Imran M
    Crit Rev Microbiol; 2018 Feb; 44(1):79-94. PubMed ID: 28421881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.
    Wong JP; DiTullio P; Parkinson S
    Future Microbiol; 2015; 10(11):1751-8. PubMed ID: 26597426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promising advances in nanobiotic-based formulations for drug specific targeting against multidrug-resistant microbes and biofilm-associated infections.
    Elfadil D; Elkhatib WF; El-Sayyad GS
    Microb Pathog; 2022 Sep; 170():105721. PubMed ID: 35970290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them.
    Khameneh B; Diab R; Ghazvini K; Fazly Bazzaz BS
    Microb Pathog; 2016 Jun; 95():32-42. PubMed ID: 26911646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ABC-Type Efflux Pump MacAB Is Involved in Protection of Serratia marcescens against Aminoglycoside Antibiotics, Polymyxins, and Oxidative Stress.
    Shirshikova TV; Sierra-Bakhshi CG; Kamaletdinova LK; Matrosova LE; Khabipova NN; Evtugyn VG; Khilyas IV; Danilova IV; Mardanova AM; Sharipova MR; Bogomolnaya LM
    mSphere; 2021 Mar; 6(2):. PubMed ID: 33692192
    [No Abstract]   [Full Text] [Related]  

  • 32. Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives.
    Hetta HF; Ramadan YN; Al-Harbi AI; A Ahmed E; Battah B; Abd Ellah NH; Zanetti S; Donadu MG
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era.
    Huh AJ; Kwon YJ
    J Control Release; 2011 Dec; 156(2):128-45. PubMed ID: 21763369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Essential Oils in the Inhibition of Efflux Pumps and Reversion of Bacterial Resistance to Antimicrobials.
    Agreles MAA; Cavalcanti IDL; Cavalcanti IMF
    Curr Microbiol; 2021 Oct; 78(10):3609-3619. PubMed ID: 34432112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.
    Nikaido H; Pagès JM
    FEMS Microbiol Rev; 2012 Mar; 36(2):340-63. PubMed ID: 21707670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.
    Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF
    mBio; 2020 Sep; 11(5):. PubMed ID: 32934086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Major Facilitator Superfamily (MFS) Efflux Pump, SCO4121, from Streptomyces coelicolor with Roles in Multidrug Resistance and Oxidative Stress Tolerance and Its Regulation by a MarR Regulator.
    Nag A; Mehra S
    Appl Environ Microbiol; 2021 Mar; 87(7):. PubMed ID: 33483304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps.
    Mahmood HY; Jamshidi S; Sutton JM; Rahman KM
    Curr Med Chem; 2016; 23(10):1062-81. PubMed ID: 26947776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efflux pumps in multidrug-resistant Acinetobacter baumannii: Current status and challenges in the discovery of efflux pumps inhibitors.
    Verma P; Tiwari M; Tiwari V
    Microb Pathog; 2021 Mar; 152():104766. PubMed ID: 33545327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Nanotherapeutics as Next-generation Anti-infective Agents: Current Trends and Future Prospectives.
    Subhaswaraj P; Syed A; Siddhardha B
    Curr Drug Discov Technol; 2020; 17(4):457-468. PubMed ID: 31309893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.